ZOETIS INC

Zoetis insider sale signals shifting confidence amid revenue cuts and leadership shake‑ups—an early warning for investors seeking a clearer view of future growth.

Zoetis insider sale: Michael McCallister sells 1,209 shares at $81.40 – a tactical take‑profit amid rising sentiment, legal risk and long‑term stake insights.

Zoetis insider buying shows confidence amid volatility – director Bisaro Paul’s new shares hint at long‑term growth prospects and a potential upside for investors.

Insider buy of 3,000 Zoetis shares by Michael McCallister signals confidence in the firm’s new drug, Tessie, amid a 50% year‑to‑date decline.

Zoetis insider buying signals confidence amid a 52‑week low – executives purchase shares after price dips, highlighting optimism for biologics and pet‑care growth.

Zoetis insider moves show long‑term confidence: Sarbaugh Keith’s March 2026 RSU exercise boosts executive stake while modest sales keep liquidity in check, signaling steady growth prospects for the animal‑health company.

Zoetis insider buys phantom stock—signaling confidence amid AI, regenerative‑therapeutics push and upbeat social‑media sentiment.

Zoetis insider buying: Kevin Esch’s modest 43‑share purchase signals leadership confidence amid market volatility and an upcoming Q4 earnings‑boost.

Zoetis insider buying signals leadership confidence and hints at future growth opportunities in animal‑health markets.